In addition to antibodies, small peptides/ligands that recognize tumor‐associated antigens/receptors have been utilized as fusion partners for TRAIL to enhance the tumor‐homing capabilities of TRAIL and inhibit tumor growth through alternative molecular pathways. Here, TNFSF10 is linked to neoplasm.